Last reviewed · How we verify
Group R
Group R, marketed by Yonsei University, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, leveraging the protection of its key patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Group R |
|---|---|
| Also known as | Continuous infusion of remifentanil at 0.05 ~ 2 mcg/kg/min with sevoflurane concentration of 1 MAC |
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- Improving Family Communication in Older Adults: A Pilot Randomized Controlled Trial (NA)
- Glofitamab in Chinese Patients With R/R DLBCL
- The Impact of Breathing Training on PPSUI: A Randomized Controlled Trial (NA)
- First-in-Human PfSPZ-LARC2 Vaccination/CHMI (PHASE1)
- Tocilizumab in Lung Transplantation (PHASE2)
- Increasing the Coverage of Severe Acute Malnutrition (SAM) Treatment in Ethiopia (NA)
- A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |